SCHEMBL20114880

SCHEMBL20114880

N#Cc1ccc(F)cc1-c1nc(-c2ccccc2)nc(-c2ccccc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
ADORA1 P30542 5/20 0.43
ADORA2A P29274 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ABCG2 Q9UNQ0 4/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPT P10636 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20843360 0.89 MEN1 (0.47) RXFP1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL20114501 0.88 ADORA1 (0.46) RXFP1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL29425208 0.87 ADORA1 (0.43) RXFP1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL1463109 0.83 KDM4E (0.46) RXFP1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL29559425 0.83 ABCG2 (0.41) RXFP1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL26581886 0.83 ALDH1A1 (0.45) RXFP1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL19943087 0.83 ABCG2 (0.46) RXFP1CYP11B1CYP11B2ADORA1ADORA2A
SCHEMBL20938177 0.81 CYP11B1 (0.44) RXFP1CYP11B1CYP11B2ADORA1ADORA2A
SCHEMBL16122458 0.81 ABCG2 (0.48) RXFP1CYP11B1CYP11B2ADORA1ADORA2A
SCHEMBL26581891 0.80 ALDH1A1 (0.43) RXFP1MEN1KMT2ACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421746-B2 Organic molecules, especially for use in organic optoelectronic devices CYNORA GMBH (DE) 2019-09-24 US disclosed
EP-3315581-B1 ORGANIC MOLECULES, IN PARTICULAR FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2019-01-02 EP disclosed
US-20180134686-A1 ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2018-05-17 US disclosed
EP-3315581-A1 ORGANIC MOLECULES, IN PARTICULAR FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2018-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134686-A1 ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES OR10J3, EPCAM, F12 RXFP1 2513/4885MEN1 2430/4885KMT2A 2180/4885
US-10421746-B2 Organic molecules, especially for use in organic optoelectronic devices OR10J3, EPCAM, F12 RXFP1 2513/4885MEN1 2430/4885KMT2A 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.